Rocket Pharmaceuticals Stock Surges 34% on FDA Alignment for Danon Disease Treatment
By Sabela Ojea
Shares of Rocket Pharmaceuticals surged 34% to $20.46 in post-market trading on Tuesday after the company said it reached alignment with the Food and Drug Administration regarding its Phase 2 trial for the treatment of Danon disease.
The Cranbury, N.J.-based pharmaceutical company said its study would evaluate the use of the investigational gene therapy RP-A501 to treat 12 patients with Danon disease.
Danon is a rare genetic disorder that has no cure, and is known for weakening the heart and movement muscles, as well as intellectual disability.
The trial will support accelerated approval of Rocket's treatment by the FDA.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 12, 2023 17:13 ET (21:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?